Key Takeaways Amvuttra drives Alnylam's top line through expanded label and as patients switch from Onpattro.Givlaari, Oxlumo, and royalties from Leqvio add incremental revenues and global growth potential.Rare disease drugs delivered $236.8M in H1 2025 revenues, up 16% year over year.Alnylam Pharmaceuticals’ (ALNY) primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the United States and the EU for treating the polyneuropathy of hereditary transthyretin-mediated (hATTR) ...